百濟神州(06160.HK):百悦澤®(澤布替尼)在加拿大獲批用於治療套細胞淋巴瘤患者
格隆匯7月27日丨百濟神州(06160.HK)於2021年7月26日(美國東部時間)宣佈,加拿大衞生部已批准百悦澤®(澤布替尼)用於治療既往至少接受過一種治療的成人套細胞淋巴瘤(MCL)患者。這是百悦澤®在2021年3月首次獲批用於治療成人華氏巨球蛋白血癥(WM)患者之後,在加拿大取得的第二項適應症的批准。
百濟神州血液學首席醫學官、醫學博士黃蔚娟表示:“百悦澤®由百濟神州的科學家們進行了特殊設計,為血液系統惡性腫瘤患者帶來深度且持久的緩解,同時減少了過去在第一代BTK抑制劑中觀察到的脱靶效應。加拿大是全球首個百悦澤®批准用於治療WM的國家。而繼今年早些時候百悦澤®在加拿大獲批用於治療WM患者後,今天又在該國獲批用於治療MCL患者。我們很高興能夠繼續與加拿大以及其他國家的患者和臨牀醫生合作,廣泛推進百悦澤®的臨牀開發計劃。目前百悦澤®已經在八種適應症中開展超過25項臨牀試驗,全球入組患者超過3100例。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.